News & Updates

The rates of positive surgical margin (PSM) with Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) are acceptable and higher in pT3 disease than in pT2, according to a study.

First-line treatment with pembrolizumab + chemotherapy maintains overall survival (OS) and progression-free survival (PFS) in patients with advanced or metastatic oesophageal cancer, according to an additional 12-month follow-up of the KEYNOTE-590* study presented at ASCO GI 2022.

The incidence of engraftment syndrome (ES), a common complication of autologous haematopoietic cell transplantation (HCT), is comparable between melphalan formulations among patients with multiple myeloma and immunoglobulin light chain amyloidosis, reveals a study.

First-line treatment with a combination of nivolumab plus ipilimumab (NIVO + IPI) continues to show long-term survival benefits over sunitinib out to 5 years in patients with advanced clear-cell renal carcinoma (RCC) with sarcomatoid features, according to the CheckMate 214 study presented at GUCS 2022.

Serum D-dimer levels appear to be insufficient at predicting colon polyp pathology and progression to malignancy, reports a recent study.

Elective upper-neck irradiation provides similar regional control, with a lower incidence of late toxicity, compared with standard whole-neck irradiation in patients with N0–N1 nasopharyngeal carcinoma (NPC), a phase III trial in China has shown.

Chinese patients receiving androgen deprivation therapy (ADT) for prostate cancer are exposed to increased risk of new-onset diabetes mellitus (DM), hyperlipidaemia and hypertension (HTN), as well as a higher likelihood of step-up pharmacotherapy for these pre-existing conditions, according to a prospective multicentre cohort study by the Chinese University of Hong Kong (CUHK) and Tuen Mun Hospital.